GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
4.2k
c/glp1science·posted 1 year ago by u/zeynep_villalobos

[Discussion] we are measuring receptor at the wrong time and calling it noise

Discussion Receipts ×2 Well Actually ×3 Sourced ×3

Thinking out loud about this: we are measuring receptor at the wrong time and calling it noise.

The GIP question, which is the most interesting unsettled thing in this field.

Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.

It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.

4,470 up / 302 down94% upvoted39 commentsid 2xwuy30 Dec 2024

39 comments

12 in this archive, depth 3

best — the order this archive was captured in

u/elin_lundgren537 points·1 year ago

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

replysharereportpermalink
[removed]219 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/noor_hovland55 points·1 year ago

dose response is not linear and nobody should assume it is

replysharereportpermalink
u/maintenance_mode_maxmaintenance475 points·1 year ago

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink
u/zeynep_villalobosOP252 points·1 year ago

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/greta_lokken111 points·1 year ago

half-life is why these are weekly and not daily

replysharereportpermalink
u/camila_kowalski280 points·1 year ago

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

replysharereportpermalink
u/zeynep_villalobosOP172 points·1 year ago

read the discussion section, that is where the honesty lives

replysharereportpermalink
u/tomas_broberg-2 points·1 year ago

the central appetite effect is doing more work than the gut effect

replysharereportpermalink
u/analog_alphabet-3 points·1 year ago

Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.

replysharereportpermalink
u/swirl_dont_shakereconstitution1 point·1 year ago

glucagon agonism sounds paradoxical until you read the energy expenditure work

replysharereportpermalink
u/sig_figs_samMOD1 point·1 year ago

Left up and flaired Explainer. This is the standard of post the board was created for.

replysharereportpermalink
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.